Guidelines on the diagnosis and management of multiple myeloma treatment: Associac ao Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2022. Part I

Maiolino, Angelo; Crusoé, Edvan de Queiroz; Martinez, Gracia Aparecida; Braga, Walter Moisés Tobias; Farias, Danielle Leão Cordeiro de; Bittencourt, Rosane Isabel; Pinto Neto, Jorge Vaz; Ribeiro, Glaciano Nogueira; Bernardo, Wanderley Marques; Tristão, Luca; Magalhães, Roberto J. P; Hungria, Vania Tietsche de Moraes.
Hematol., Transfus. Cell Ther. (Impr.) ; 44(3): 410-418, July-Sept. 2022.
Artículo en Inglés | LILACS | ID: biblio-1405010

Documentos relacionados

  1. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
  2. Revisiting the Case of Sarah Newbury's Death from Mollities Ossium.
  3. Screening in Multiple Myeloma and Its Precursors: Are We There Yet?
  4. Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma.
  5. Chromothripsis as a pathogenic driver of multiple myeloma.
  6. Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation.
  7. How to Diagnose, Treat, and Monitor Treatment Response in Patients with Multiple Myeloma.
  8. Development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx).
  9. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
  10. [Multiple myeloma : an overview of advances in biology and treatment].